- Home
- CYH vs VSTM Comparison
CYH vs VSTM Comparison
Compare CYH & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | VSTM |
|---|---|---|
| Founded | 1985 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.2M | 470.7M |
| IPO Year | 2000 | 2011 |
Fundamental Metrics
Financial Performance| Metric | CYH | VSTM |
|---|---|---|
| Price | $2.71 | $4.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $3.28 | ★ $16.50 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 196.67 | 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,485,000,000.00 | $30,914,000.00 |
| Revenue This Year | N/A | $282.64 |
| Revenue Next Year | $2.17 | $72.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $2.39 | $4.00 |
| 52 Week High | $4.43 | $11.25 |
Technical Indicators
Market Signals| Indicator | CYH | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 37.62 |
| Support Level | $2.71 | $4.00 |
| Resistance Level | $3.25 | $6.67 |
| Average True Range (ATR) | 0.11 | 0.28 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 4.92 | 28.40 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.